A Phase 2 interventional study of Risankizumab 600 mg IV and Risankizumab 180 mg SC in Crohn Disease, sponsored by AbbVie. Completed at 28 sites in 9 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-04-24.
Sponsored by AbbVie · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing risankizumab in Crohn Disease — 7 open to participants now, 10 under way, 6 of them phase 3. risankizumab · Crohn Disease.
Among the 16 studies testing risankizumab in Crohn Disease, this one is the 13th largest by enrollment, is the only one that started in 2015, is one of 4 in phase 2, and was the 2nd registered.
1,994 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →7 of the 16 studies testing risankizumab in Crohn Disease are open now, in 12 countries. Recruiting first, the newest first:
Yuki Horio · Sites in Japan
Ages 15+
AbbVie · Sites in United States, Canada, Israel and 2 more countries
Ages 18–75
Janssen Research & Development, LLC · Sites in United States, Austria, Belgium and 14 more countries
Ages 18+
Shaare Zedek Medical Center · Sites in Israel
Ages 6–18
AbbVie · Sites in United States, Austria, Belgium and 30 more countries
Ages 18–75
By country, each count listing its studies:
risankizumab: first FDA approval 2019 (SKYRIZI), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 1 started in 2015.
This study's enrollment of 65 is close to the median of 67 across 1,262 interventional studies indexed under Crohn Disease.
Median enrollment 275 across the 16 interventional studies. Of the 6 that completed or were terminated, 4 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 16 have an industry lead sponsor. The 5 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
55 studies in Crohn Disease by AbbVie: 6 open now, 14 under way, 6 of them phase 3. Of 38 finished, 28 (74%) have results posted.
Among the 55 studies in Crohn Disease by AbbVie, this one is the 23rd largest by enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2015, is one of 8 in phase 2, and was the 23rd registered.
AbbVie’s Crohn Disease studies by the year they started, since 2007.
1 of the studies testing risankizumab in Crohn Disease that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06063967Phase 3AbbVieA Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies testing risankizumab in Crohn Disease, from their registry updates:
Among AbbVie’s 55 in Crohn Disease:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study was to investigate long-term safety of risankizumab (BI 655066/ABBV-066) in participants with moderately to severely active Crohn's disease who showed a clinical response or remission on previous treatment with risankizumab in Study NCT02031276 (BI trial 1311.6/ AbbVie M15-993) and were now receiving long-term treatment. Additional objectives of this study were to further investigate long-term efficacy, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of risankizumab.
This was a single group, open-label long-term extension study that assessed the long-term safety, efficacy, and pharmacokinetics of risankizumab in participants with moderately to severely active Crohn's disease. This study was terminated early by AbbVie to enable participants who completed the study to rollover into Study NCT03105102 (AbbVie M16-000 Sub-Study 3 [Phase 3 OLE study]) for further OLE treatment within the Phase 3 program, which allows for risankizumab dose escalation if needed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants with Crohn's disease, who had successfully completed the preceding trial NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). Successful treatment is defined as:
Female participants:
Male participants:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Maintenance treatment with risankizumab 180 mg administered subcutaneously (SC) every 8 weeks (q8w) from Visit 2 through the end of trial (EOT) visit. Participants who re-gained their clinical response following the re-induction treatment could continue with maintenance treatment beginning at Visit 5.
Drug: Risankizumab 600 mg IV · Drug: Risankizumab 180 mg SC
Re-induction treatment; 3 infusions every 4 weeks, after which eligibility was assessed if clinical response was re-gained
Also known as: BI 655066, ABBV-066
Maintenance treatment every 8 weeks (q8w) from Visit 2 through the end of trial (EOT) visit. Participants who re-gained their clinical response following the re-induction treatment could continue with maintenance treatment beginning at Visit 5.
Also known as: BI 655066, ABBV-066
Number of Participants With Adverse Events
A treatment emergent adverse event was defined as an event that occurred or worsened on or after the first dose of study drug through 140 days after the last dose in the current study for participants not rolling over into M16-000 Sub-study 3 or until the first dose of study drug in NCT03105102. All treatment-emergent serious and nonserious adverse events were collected, whether elicited or spontaneously reported by the participant.
Time frame: From the time of study drug administration until 140 days after the last dose of study drug in the current study or until the first dose of study drug in NCT03105102 (AbbVie M16-000 Sub-study 3), up to 4 years for participants who rolled-over
Percentage of Participants Achieving Crohn's Disease Activity Index (CDAI) Clinical Remission by Visit
The Crohn's Disease Activity Index (CDAI) is a composite instrument that includes participant symptoms evaluated over 7 days (abdominal pain, stool frequency and general well-being), as well as physical and laboratory findings. These items are scored individually, weighted, and do not contribute equally to the overall score. The CDAI is derived from summing up the weighted individual scores of eight items. CDAI approximately ranges from 0 to 600 with higher scores indicating more severe disease. Clinical remission is defined as CDAI score \< 150.
Time frame: Weeks 0, 4, 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104, 112, 120, 128, 136, 144, 152, 160, 168, 176, and 184
Percentage of Participants Achieving Crohn's Disease Activity Index (CDAI) Clinical Response by Visit
The Crohn's Disease Activity Index (CDAI) is a composite instrument that includes participant symptoms evaluated over 7 days (abdominal pain, stool frequency and general well-being), as well as physical and laboratory findings. These items are scored individually, weighted, and do not contribute equally to the overall score. The CDAI is derived from summing up the weighted individual scores of eight items. CDAI approximately ranges from 0 to 600 with higher scores indicating more severe disease. Clinical response is defined as CDAI score \< 150 or a reduction from baseline of at least 100 points. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993).
Time frame: Weeks 0, 4, 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104, 112, 120, 128, 136, 144, 152, 160, 168, 176, and 184
Percentage of Participants Achieving Patient Reported Outcome 2 (PRO-2) Remission by Visit
The PRO-2 is calculated based on the sum of the weighted patient-reported subscores of CDAI for liquid or soft stool frequency \[SF\] plus abdominal pain \[AP\] in the 7 days prior to the study visit. The PRO-2 score is calculated by adding the values of the summed stool frequency scores multiplied by 2 plus the summed abdominal pain scores multiplied by 5. The SF and AP score at an assessment visit was the average of the daily values reported during the 7 days preceding the scheduled assessment visit. PRO-2 scores range from 0 to no upper limit with higher scores indicating more severe disease. Remission is defined as PRO-2 score \< 75.
Time frame: Weeks 0, 4, 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104, 112, 120, 128, 136, 144, 152, 160, 168, 176, and 184
Percentage of Participants Achieving Patient Reported Outcome 2 (PRO-2) Response by Visit
The PRO-2 is calculated based on the sum of the weighted patient-reported subscores of CDAI for liquid or soft stool frequency \[SF\] plus abdominal pain \[AP\] in the 7 days prior to the study visit. The PRO-2 score is calculated by adding the values of the summed stool frequency scores multiplied by 2 plus the summed abdominal pain scores multiplied by 5. The SF and AP score at an assessment visit was the average of the daily values reported during the 7 days preceding the scheduled assessment visit. PRO-2 scores range from 0 to no upper limit with higher scores indicating more severe disease. PRO-2 response is defined as a decrease from baseline of 50 points or more. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993).
Time frame: Weeks 0, 4, 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104, 112, 120, 128, 136, 144, 152, 160, 168, 176, and 184
Percentage of Participants Achieving Crohn's Disease Endoscopic Index of Severity (CDEIS) Remission by Visit
CDEIS is an index for determining the severity of Crohn's disease. The CDEIS considers deep ulcerations, superficial ulcerations, ulcerated and non-ulcerated surface, and the presence of ulcerated/non-ulcerated stenosis evaluated in 5 pre-defined segments of the colon (ileum, ascending colon, transverse colon, descending colon and sigmoid loop, and rectum). The score ranges from 0 to 44 where higher scores indicate more severe endoscopic activity. Remission is defined as a score of 4 or less, by visit (or for participants with initial isolated ileitis a score of 2 or less).
Time frame: Weeks 0, 48, 104, 152, and 200
Percentage of Participants Achieving Crohn's Disease Endoscopic Index of Severity (CDEIS) Response by Visit
CDEIS is an index for determining the severity of Crohn's disease. The CDEIS considers deep ulcerations, superficial ulcerations, ulcerated and non-ulcerated surface, and the presence of ulcerated/non-ulcerated stenosis evaluated in 5 pre-defined segments of the colon (ileum, ascending colon, transverse colon, descending colon and sigmoid loop, and rectum). The score ranges from 0 to 44 where higher scores indicate more severe endoscopic activity. Response is defined as a score of 7 or less (or for participants with initial isolated ileitis \> 50% reduction from baseline). Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993).
Time frame: Weeks 0, 48, 104, 152, and 200
Percentage of Participants With Mucosal Healing by Visit
Mucosal healing is defined as Crohn's Disease Endoscopy Index of Severity (CDEIS) ulcerations sub-score (deep ulceration, superficial ulceration, ulcerated stenosis) of 0 as evaluated in 5 pre-defined segments of the colon (ileum, ascending colon, transverse colon, descending colon and sigmoid loop, and rectum). The overall CDEIS score ranges from 0 to 44 where higher scores indicate more severe endoscopic activity.
Time frame: Weeks 0, 48, 104, 152, and 200
Percentage of Participants Achieving Deep Remission by Visit
Deep remission is defined as clinical remission (CDAI \< 150) and CDEIS remission (CDEIS score of 4 or less, by visit or for participants with initial isolated ileitis a score of 2 or less).
Time frame: Weeks 0, 48, 104, 152, and 200
Percentage of Participants Achieving Inflammatory Bowel Disease Questionnaire (IBDQ) Remission by Visit
The Inflammatory Bowel Disease Questionnaire (IBDQ) measures the effects of inflammatory bowel disease on daily function and quality of life. The IBDQ consists of 32 questions which address symptoms as a result of Crohn's disease: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Each question is answered on a scale from 1 (all the time) to 7 (none of the time); the total score ranges from 32 (worst) to 224 (best). IBDQ remission is defined as IBDQ total score \> 170 points.
Time frame: Weeks 0, 24, 48, 72, 96, 120, 144, 168, and 192
Percentage of Participants Achieving Inflammatory Bowel Disease Questionnaire (IBDQ) Response by Visit
The Inflammatory Bowel Disease Questionnaire (IBDQ) measures the effects of inflammatory bowel disease on daily function and quality of life. The IBDQ consists of 32 questions which address symptoms as a result of Crohn's disease: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Each question is answered on a scale from 1 (all the time) to 7 (none of the time); the total score ranges from 32 (worst) to 224 (best). IBDQ response is defined as increase in IBDQ total score \>16 points from baseline. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993).
Time frame: Weeks 0, 24, 48, 72, 96, 120, 144, 168, and 192
Mean Change From Baseline in Crohn's Disease Activity Index (CDAI) by Visit
The Crohn's Disease Activity Index (CDAI) is a composite instrument that includes participant symptoms evaluated over 7 days (abdominal pain, stool frequency and general well-being), as well as physical and laboratory findings. These items are scored individually, weighted, and do not contribute equally to the overall score. The CDAI is derived from summing up the weighted individual scores of eight items. CDAI approximately ranges from 0 to 600 with higher scores indicating more severe disease. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). A negative change from baseline indicates improvement.
Time frame: Weeks 0, 4, 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104, 112, 120, 128, 136, 144, 152, 160, 168, 176, and 184
Mean Change From Baseline in Patient Reported Outcome 2 (PRO-2) Scores by Visit
The PRO-2 is calculated based on the sum of the weighted patient-reported subscores of CDAI for liquid or soft stool frequency \[SF\] plus abdominal pain \[AP\] in the 7 days prior to the study visit. The PRO-2 score is calculated by adding the values of the summed stool frequency scores multiplied by 2 plus the summed abdominal pain scores multiplied by 5. The SF and AP score at an assessment visit was the average of the daily values reported during the 7 days preceding the scheduled assessment visit. PRO-2 scores range from 0 to no upper limit with higher scores indicating more severe disease. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). A negative change from baseline indicates improvement.
Time frame: Weeks 0, 4, 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104, 112, 120, 128, 136, 144, 152, 160, 168, 176, and 184
Mean Change From Baseline in Crohn's Disease Endoscopic Index of Severity (CDEIS) by Visit
CDEIS is an index for determining the severity of Crohn's disease. The CDEIS considers deep ulcerations, superficial ulcerations, ulcerated and non-ulcerated surface, and the presence of ulcerated/non-ulcerated stenosis evaluated in 5 pre-defined segments of the colon (ileum, ascending colon, transverse colon, descending colon and sigmoid loop, and rectum). The score ranges from 0 to 44 where higher scores indicate more severe endoscopic activity. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). A negative change from baseline indicates improvement.
Time frame: Weeks 0, 48, 104, 152, and 200
Mean Change From Baseline in Simple Endoscopic Score (SES-CD) by Visit
SES-CD is calculated based the sum of individual segment values for four endoscopic variables (presence and size of ulcers, ulcerated surface, affected surface and presence of narrowing). Each variable in each segment is scored 0 to 3 resulting in SES-CD values ranging from 0 to 56 with higher scores indicating more severe disease. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). A negative change from baseline indicates improvement.
Time frame: Weeks 0, 48, 104, 152, and 200
Mean Change From Baseline in Stool Frequency (SF) By Visit
Participants were asked to record the frequency of liquid stools on a daily basis. The number of liquid stools in the prior 7 days was summed. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). Negative values indicate improvement from baseline.
Time frame: Weeks 0, 4, 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104, 112, 120, 128, 136, 144, 152, 160, 168, 176, and 184
Mean Change From Baseline in Abdominal Pain (AP) Score By Visit
Participants were asked to rate and record daily abdominal pain on a scale of 0 to 3 \[none (0), mild (1), moderate (2) and severe (3)\]. The ratings in the prior 7 days were summed. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). Negative values indicate improvement from baseline.
Time frame: Weeks 0, 4, 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104, 112, 120, 128, 136, 144, 152, 160, 168, 176, and 184
Mean Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score by Visit
The Inflammatory Bowel Disease Questionnaire (IBDQ) measures the effects of inflammatory bowel disease on daily function and quality of life. The IBDQ consists of 32 questions which address symptoms as a result of Crohn's disease: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Each question is answered on a scale from 1 (all the time) to 7 (none of the time); the total score ranges from 32 (worst) to 224 (best). Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). Positive values indicate improvement from baseline.
Time frame: Weeks 0, 24, 48, 72, 96, 120, 144, 168, and 192
Mean Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Symptom Domain Score by Visit
The Inflammatory Bowel Disease Questionnaire (IBDQ) measures the effects of inflammatory bowel disease on daily function and quality of life. The IBDQ consists of 32 questions which address symptoms as a result of Crohn's disease: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Each question is answered on a scale from 1 (all the time) to 7 (none of the time); the total score ranges from 32 (worst) to 224 (best). Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). Positive values indicate improvement from baseline.
Time frame: Weeks 0, 24, 48, 72, 96, 120, 144, 168, and 192
Mean Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Systemic System Domain Score by Visit
The Inflammatory Bowel Disease Questionnaire (IBDQ) measures the effects of inflammatory bowel disease on daily function and quality of life. The IBDQ consists of 32 questions which address symptoms as a result of Crohn's disease: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Each question is answered on a scale from 1 (all the time) to 7 (none of the time); the total score ranges from 32 (worst) to 224 (best). Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). Positive values indicate improvement from baseline.
Time frame: Weeks 0, 24, 48, 72, 96, 120, 144, 168, and 192
Mean Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Social Function Domain Score by Visit
The Inflammatory Bowel Disease Questionnaire (IBDQ) measures the effects of inflammatory bowel disease on daily function and quality of life. The IBDQ consists of 32 questions which address symptoms as a result of Crohn's disease: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Each question is answered on a scale from 1 (all the time) to 7 (none of the time); the total score ranges from 32 (worst) to 224 (best). Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). Positive values indicate improvement from baseline.
Time frame: Weeks 0, 24, 48, 72, 96, 120, 144, 168, and 192
Mean Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Emotional Function Domain Score by Visit
The Inflammatory Bowel Disease Questionnaire (IBDQ) measures the effects of inflammatory bowel disease on daily function and quality of life. The IBDQ consists of 32 questions which address symptoms as a result of Crohn's disease: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Each question is answered on a scale from 1 (all the time) to 7 (none of the time); the total score ranges from 32 (worst) to 224 (best). Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). Positive values indicate improvement from baseline.
Time frame: Weeks 0, 24, 48, 72, 96, 120, 144, 168, and 192
Mean Change From Baseline in High-Sensitivity C-reactive Protein (Hs-CRP) by Visit
Concentration of serum high-sensitivity C-reactive Protein (hs-CRP) was analyzed by a central laboratory. It is a general marker of inflammation that is sensitive to acute changes in inflammatory response, and higher levels indicate more inflammation. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). Negative values indicate improvement from baseline.
Time frame: Weeks 0, 8, 24, 40, 56, 72, 88, 104, 120, 128, 136, 152, 160, 176, and 184
Mean Change From Baseline in Fecal Calprotectin (FCP) Profile by Visit
Fecal calprotectin (FCP) is an indicator of inflammation in the colon with higher levels indicative of higher levels of inflammation. Stool samples were analyzed by a central laboratory for fecal calprotectin levels. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). Negative values indicate improvement from baseline.
Time frame: Weeks 0, 24, 56, 88, 120, 152, and 184
| Milestone | All Risankizumab |
|---|---|
| Started | 65 |
| Completed | 44 |
| Not completed | 21 |
| Withdrew: Adverse event | 7 |
| Withdrew: Withdrew consent | 5 |
| Withdrew: Loss of efficacy | 2 |
| Withdrew: Pregnancy | 2 |
| Withdrew: Subject decision | 2 |
| Withdrew: Lack of response | 1 |
| Withdrew: Reproductive plans | 1 |
| Withdrew: Surgery planned-- not done | 1 |
A treatment emergent adverse event was defined as an event that occurred or worsened on or after the first dose of study drug through 140 days after the last dose in the current study for participants not rolling over into M16-000 Sub-study 3 or until the first dose of study drug in NCT03105102. All treatment-emergent serious and nonserious adverse events were collected, whether elicited or spontaneously reported by the participant.
| Participants | Risankizumab 600 mg IV | Risankizumab 180 mg SC | All Risankizumab |
|---|---|---|---|
| Number of Participants With Adverse Events | 2 | 60 | 60 |
The Crohn's Disease Activity Index (CDAI) is a composite instrument that includes participant symptoms evaluated over 7 days (abdominal pain, stool frequency and general well-being), as well as physical and laboratory findings. These items are scored individually, weighted, and do not contribute equally to the overall score. The CDAI is derived from summing up the weighted individual scores of eight items. CDAI approximately ranges from 0 to 600 with higher scores indicating more severe disease. Clinical remission is defined as CDAI score \< 150.
| percentage of participants | Risankizumab 600 mg IV | Risankizumab 180 mg SC |
|---|---|---|
| Week 0 | 25.00 | 72.31 |
| Week 4 | 25.00 | — |
| Week 8 | 25.00 | 73.85 |
| Week 16 | — | 71.88 |
| Week 24 | — | 74.60 |
| Week 32 | — | 78.69 |
| Week 40 | — | 81.67 |
| Week 48 | — | 79.31 |
| Week 56 | — | 80.70 |
| Week 64 | — | 87.27 |
| Week 72 | — | 83.33 |
| Week 80 | — | 79.25 |
| Week 88 | — | 78.43 |
| Week 96 | — | 84.62 |
| Week 104 | — | 85.71 |
| Week 112 | — | 87.50 |
| Week 120 | — | 83.33 |
| Week 128 | — | 86.96 |
| Week 136 | — | 76.92 |
| Week 144 | — | 78.38 |
| Week 152 | — | 76.67 |
| Week 160 | — | 78.26 |
| Week 168 | — | 70.59 |
| Week 176 | — | 60.00 |
| Week 184 | — | 40.00 |
The Crohn's Disease Activity Index (CDAI) is a composite instrument that includes participant symptoms evaluated over 7 days (abdominal pain, stool frequency and general well-being), as well as physical and laboratory findings. These items are scored individually, weighted, and do not contribute equally to the overall score. The CDAI is derived from summing up the weighted individual scores of eight items. CDAI approximately ranges from 0 to 600 with higher scores indicating more severe disease. Clinical response is defined as CDAI score \< 150 or a reduction from baseline of at least 100 points. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993).
| percentage of participants | Risankizumab 600 mg IV | Risankizumab 180 mg SC |
|---|---|---|
| Week 0 | 50.00 | 90.77 |
| Week 4 | 75.00 | — |
| Week 8 | 100.00 | 98.46 |
| Week 16 | — | 92.19 |
| Week 24 | — | 95.24 |
| Week 32 | — | 95.08 |
| Week 40 | — | 96.67 |
| Week 48 | — | 94.83 |
| Week 56 | — | 92.98 |
| Week 64 | — | 96.36 |
| Week 72 | — | 94.44 |
| Week 80 | — | 92.45 |
| Week 88 | — | 92.16 |
| Week 96 | — | 92.31 |
| Week 104 | — | 93.88 |
| Week 112 | — | 93.75 |
| Week 120 | — | 93.75 |
| Week 128 | — | 93.48 |
| Week 136 | — | 92.31 |
| Week 144 | — | 91.89 |
| Week 152 | — | 93.33 |
| Week 160 | — | 91.30 |
| Week 168 | — | 82.35 |
| Week 176 | — | 80.00 |
| Week 184 | — | 80.00 |
The PRO-2 is calculated based on the sum of the weighted patient-reported subscores of CDAI for liquid or soft stool frequency \[SF\] plus abdominal pain \[AP\] in the 7 days prior to the study visit. The PRO-2 score is calculated by adding the values of the summed stool frequency scores multiplied by 2 plus the summed abdominal pain scores multiplied by 5. The SF and AP score at an assessment visit was the average of the daily values reported during the 7 days preceding the scheduled assessment visit. PRO-2 scores range from 0 to no upper limit with higher scores indicating more severe disease. Remission is defined as PRO-2 score \< 75.
| percentage of participants | Risankizumab 600 mg IV | Risankizumab 180 mg SC |
|---|---|---|
| Week 0 | 25.00 | 73.85 |
| Week 4 | 25.00 | — |
| Week 8 | 50.00 | 80.00 |
| Week 16 | — | 78.13 |
| Week 24 | — | 77.78 |
| Week 32 | — | 85.25 |
| Week 40 | — | 83.33 |
| Week 48 | — | 82.76 |
| Week 56 | — | 87.72 |
| Week 64 | — | 81.82 |
| Week 72 | — | 81.48 |
| Week 80 | — | 81.13 |
| Week 88 | — | 82.35 |
| Week 96 | — | 84.62 |
| Week 104 | — | 85.71 |
| Week 112 | — | 91.67 |
| Week 120 | — | 85.42 |
| Week 128 | — | 89.13 |
| Week 136 | — | 87.50 |
| Week 144 | — | 86.49 |
| Week 152 | — | 86.67 |
| Week 160 | — | 73.91 |
| Week 168 | — | 77.78 |
| Week 176 | — | 60.00 |
| Week 184 | — | 40.00 |
The PRO-2 is calculated based on the sum of the weighted patient-reported subscores of CDAI for liquid or soft stool frequency \[SF\] plus abdominal pain \[AP\] in the 7 days prior to the study visit. The PRO-2 score is calculated by adding the values of the summed stool frequency scores multiplied by 2 plus the summed abdominal pain scores multiplied by 5. The SF and AP score at an assessment visit was the average of the daily values reported during the 7 days preceding the scheduled assessment visit. PRO-2 scores range from 0 to no upper limit with higher scores indicating more severe disease. PRO-2 response is defined as a decrease from baseline of 50 points or more. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993).
| percentage of participants | Risankizumab 600 mg IV | Risankizumab 180 mg SC |
|---|---|---|
| Week 0 | 50.00 | 83.08 |
| Week 4 | 50.00 | — |
| Week 8 | 50.00 | 86.15 |
| Week 16 | — | 90.63 |
| Week 24 | — | 92.06 |
| Week 32 | — | 86.89 |
| Week 40 | — | 98.33 |
| Week 48 | — | 93.10 |
| Week 56 | — | 91.23 |
| Week 64 | — | 90.91 |
| Week 72 | — | 88.89 |
| Week 80 | — | 88.68 |
| Week 88 | — | 86.27 |
| Week 96 | — | 88.46 |
| Week 104 | — | 87.76 |
| Week 112 | — | 87.50 |
| Week 120 | — | 91.67 |
| Week 128 | — | 91.30 |
| Week 136 | — | 92.50 |
| Week 144 | — | 89.19 |
| Week 152 | — | 93.33 |
| Week 160 | — | 86.96 |
| Week 168 | — | 83.33 |
| Week 176 | — | 100.00 |
| Week 184 | — | 100.00 |
CDEIS is an index for determining the severity of Crohn's disease. The CDEIS considers deep ulcerations, superficial ulcerations, ulcerated and non-ulcerated surface, and the presence of ulcerated/non-ulcerated stenosis evaluated in 5 pre-defined segments of the colon (ileum, ascending colon, transverse colon, descending colon and sigmoid loop, and rectum). The score ranges from 0 to 44 where higher scores indicate more severe endoscopic activity. Remission is defined as a score of 4 or less, by visit (or for participants with initial isolated ileitis a score of 2 or less).
| percentage of participants | Risankizumab 180 mg SC |
|---|---|
| Week 0 | 42.86 |
| Week 48 | 56.45 |
| Week 104 | 62.79 |
| Week 152 | 58.97 |
| Week 200 | 85.71 |
CDEIS is an index for determining the severity of Crohn's disease. The CDEIS considers deep ulcerations, superficial ulcerations, ulcerated and non-ulcerated surface, and the presence of ulcerated/non-ulcerated stenosis evaluated in 5 pre-defined segments of the colon (ileum, ascending colon, transverse colon, descending colon and sigmoid loop, and rectum). The score ranges from 0 to 44 where higher scores indicate more severe endoscopic activity. Response is defined as a score of 7 or less (or for participants with initial isolated ileitis \> 50% reduction from baseline). Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993).
| percentage of participants | Risankizumab 180 mg SC |
|---|---|
| Week 0 | 58.73 |
| Week 48 | 72.58 |
| Week 104 | 81.40 |
| Week 152 | 82.05 |
| Week 200 | 100.00 |
Mucosal healing is defined as Crohn's Disease Endoscopy Index of Severity (CDEIS) ulcerations sub-score (deep ulceration, superficial ulceration, ulcerated stenosis) of 0 as evaluated in 5 pre-defined segments of the colon (ileum, ascending colon, transverse colon, descending colon and sigmoid loop, and rectum). The overall CDEIS score ranges from 0 to 44 where higher scores indicate more severe endoscopic activity.
| percentage of participants | Risankizumab 180 mg SC |
|---|---|
| Week 0 | 29.69 |
| Week 48 | 35.48 |
| Week 104 | 39.53 |
| Week 152 | 43.59 |
| Week 200 | 42.86 |
Deep remission is defined as clinical remission (CDAI \< 150) and CDEIS remission (CDEIS score of 4 or less, by visit or for participants with initial isolated ileitis a score of 2 or less).
| percentage of participants | Risankizumab 180 mg SC |
|---|---|
| Week 0 | 34.92 |
| Week 48 | 47.54 |
| Week 104 | 53.49 |
| Week 152 | 42.86 |
| Week 200 | 0.00 |
The Inflammatory Bowel Disease Questionnaire (IBDQ) measures the effects of inflammatory bowel disease on daily function and quality of life. The IBDQ consists of 32 questions which address symptoms as a result of Crohn's disease: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Each question is answered on a scale from 1 (all the time) to 7 (none of the time); the total score ranges from 32 (worst) to 224 (best). IBDQ remission is defined as IBDQ total score \> 170 points.
| percentage of participants | Risankizumab 180 mg SC |
|---|---|
| Week 0 | 62.50 |
| Week 24 | 58.46 |
| Week 48 | 70.00 |
| Week 72 | 69.23 |
| Week 96 | 72.55 |
| Week 120 | 70.83 |
| Week 144 | 65.00 |
| Week 168 | 69.57 |
| Week 192 | 66.67 |
The Inflammatory Bowel Disease Questionnaire (IBDQ) measures the effects of inflammatory bowel disease on daily function and quality of life. The IBDQ consists of 32 questions which address symptoms as a result of Crohn's disease: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Each question is answered on a scale from 1 (all the time) to 7 (none of the time); the total score ranges from 32 (worst) to 224 (best). IBDQ response is defined as increase in IBDQ total score \>16 points from baseline. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993).
| percentage of participants | Risankizumab 180 mg SC |
|---|---|
| Week 0 | 92.19 |
| Week 24 | 89.23 |
| Week 48 | 95.00 |
| Week 72 | 88.46 |
| Week 96 | 90.20 |
| Week 120 | 95.83 |
| Week 144 | 92.50 |
| Week 168 | 86.96 |
| Week 192 | 100.00 |
The Crohn's Disease Activity Index (CDAI) is a composite instrument that includes participant symptoms evaluated over 7 days (abdominal pain, stool frequency and general well-being), as well as physical and laboratory findings. These items are scored individually, weighted, and do not contribute equally to the overall score. The CDAI is derived from summing up the weighted individual scores of eight items. CDAI approximately ranges from 0 to 600 with higher scores indicating more severe disease. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). A negative change from baseline indicates improvement.
| units on a scale | Risankizumab 600 mg IV | Risankizumab 180 mg SC |
|---|---|---|
| Week 0 | -50.70 ± 84.565 | -198.47 ± 101.762 |
| Week 4 | -92.68 ± 40.688 | — |
| Week 8 | -119.40 ± 32.967 | -206.75 ± 83.580 |
| Week 16 | — | -205.93 ± 92.837 |
| Week 24 | — | -194.34 ± 82.840 |
The PRO-2 is calculated based on the sum of the weighted patient-reported subscores of CDAI for liquid or soft stool frequency \[SF\] plus abdominal pain \[AP\] in the 7 days prior to the study visit. The PRO-2 score is calculated by adding the values of the summed stool frequency scores multiplied by 2 plus the summed abdominal pain scores multiplied by 5. The SF and AP score at an assessment visit was the average of the daily values reported during the 7 days preceding the scheduled assessment visit. PRO-2 scores range from 0 to no upper limit with higher scores indicating more severe disease. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). A negative change from baseline indicates improvement.
| units on a scale | Risankizumab 600 mg IV | Risankizumab 180 mg SC |
|---|---|---|
| Week 0 | -27.75 ± 48.979 | -105.46 ± 58.807 |
| Week 4 | -35.25 ± 27.011 | — |
| Week 8 | -53.75 ± 24.405 | -109.53 ± 49.419 |
| Week 16 | — | -108.32 ± 52.848 |
| Week 24 | — | -105.40 ± 50.167 |
| Week 32 | — | -109.41 ± 56.459 |
| Week 40 | — | -116.33 ± 43.511 |
| Week 48 | — | -111.29 ± 48.048 |
| Week 56 | — | -115.54 ± 51.279 |
| Week 64 | — | -113.02 ± 57.338 |
| Week 72 | — | -112.11 ± 56.819 |
| Week 80 | — | -106.42 ± 58.710 |
| Week 88 | — | -108.67 ± 51.214 |
| Week 96 | — | -109.81 ± 50.927 |
| Week 104 | — | -109.10 ± 49.562 |
| Week 112 | — | -109.75 ± 52.951 |
| Week 120 | — | -111.10 ± 47.360 |
| Week 128 | — | -113.02 ± 50.738 |
| Week 136 | — | -113.00 ± 51.575 |
| Week 144 | — | -115.35 ± 53.460 |
| Week 152 | — | -109.17 ± 56.659 |
| Week 160 | — | -96.70 ± 54.018 |
| Week 168 | — | -111.09 ± 55.287 |
| Week 176 | — | -103.06 ± 42.717 |
| Week 184 | — | -129.13 ± 70.484 |
CDEIS is an index for determining the severity of Crohn's disease. The CDEIS considers deep ulcerations, superficial ulcerations, ulcerated and non-ulcerated surface, and the presence of ulcerated/non-ulcerated stenosis evaluated in 5 pre-defined segments of the colon (ileum, ascending colon, transverse colon, descending colon and sigmoid loop, and rectum). The score ranges from 0 to 44 where higher scores indicate more severe endoscopic activity. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). A negative change from baseline indicates improvement.
| units on a scale | Risankizumab 180 mg SC |
|---|---|
| Week 0 | -8.08 ± 5.973 |
| Week 48 | -9.32 ± 6.014 |
| Week 104 | -9.24 ± 6.035 |
| Week 152 | -9.75 ± 7.254 |
| Week 200 | -10.76 ± 5.209 |
SES-CD is calculated based the sum of individual segment values for four endoscopic variables (presence and size of ulcers, ulcerated surface, affected surface and presence of narrowing). Each variable in each segment is scored 0 to 3 resulting in SES-CD values ranging from 0 to 56 with higher scores indicating more severe disease. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). A negative change from baseline indicates improvement.
| units on a scale | Risankizumab 180 mg SC |
|---|---|
| Week 0 | -9.63 ± 8.001 |
| Week 48 | -12.35 ± 7.753 |
| Week 104 | -11.56 ± 8.060 |
| Week 152 | -12.63 ± 9.139 |
| Week 200 | -13.36 ± 7.521 |
Participants were asked to record the frequency of liquid stools on a daily basis. The number of liquid stools in the prior 7 days was summed. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). Negative values indicate improvement from baseline.
| number of liquid stools in prior 7 days | Risankizumab 600 mg IV | Risankizumab 180 mg SC |
|---|---|---|
| Week 0 | -0.46 ± 2.319 | -4.13 ± 3.273 |
| Week 4 | -0.46 ± 1.584 | — |
| Week 8 | -1.07 ± 1.421 | -4.22 ± 3.160 |
| Week 16 | — | -4.10 ± 3.223 |
| Week 24 | — | -4.19 ± 3.209 |
| Week 32 | — | -4.08 ± 3.536 |
| Week 40 | — | -4.58 ± 3.037 |
| Week 48 | — | -4.31 ± 3.278 |
| Week 56 | — | -4.48 ± 3.282 |
| Week 64 | — | -4.41 ± 3.514 |
| Week 72 | — | -4.25 ± 3.513 |
| Week 80 | — | -4.00 ± 3.469 |
| Week 88 | — | -4.04 ± 3.331 |
| Week 96 | — | -4.27 ± 3.037 |
| Week 104 | — | -4.00 ± 2.943 |
| Week 112 | — | -3.91 ± 2.951 |
| Week 120 | — | -3.99 ± 2.840 |
| Week 128 | — | -4.05 ± 3.060 |
| Week 136 | — | -3.95 ± 3.137 |
| Week 144 | — | -4.13 ± 3.308 |
| Week 152 | — | -4.00 ± 3.150 |
| Week 160 | — | -3.71 ± 3.044 |
| Week 168 | — | -4.08 ± 3.353 |
| Week 176 | — | -3.61 ± 2.583 |
| Week 184 | — | -4.50 ± 3.881 |
Participants were asked to rate and record daily abdominal pain on a scale of 0 to 3 \[none (0), mild (1), moderate (2) and severe (3)\]. The ratings in the prior 7 days were summed. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). Negative values indicate improvement from baseline.
| units on a scale | Risankizumab 600 mg IV | Risankizumab 180 mg SC |
|---|---|---|
| Week 0 | -0.61 ± 1.006 | -1.36 ± 0.885 |
| Week 4 | -0.82 ± 0.768 | — |
| Week 8 | -1.11 ± 0.357 | -1.44 ± 0.746 |
| Week 16 | — | -1.45 ± 0.773 |
| Week 24 | — | -1.33 ± 0.804 |
| Week 32 | — | -1.49 ± 0.760 |
| Week 40 | — | -1.49 ± 0.766 |
| Week 48 | — | -1.46 ± 0.720 |
| Week 56 | — | -1.51 ± 0.815 |
| Week 64 | — | -1.47 ± 0.825 |
| Week 72 | — | -1.50 ± 0.839 |
| Week 80 | — | -1.44 ± 0.816 |
| Week 88 | — | -1.49 ± 0.787 |
| Week 96 | — | -1.43 ± 0.881 |
| Week 104 | — | -1.52 ± 0.861 |
| Week 112 | — | -1.57 ± 0.890 |
| Week 120 | — | -1.58 ± 0.735 |
| Week 128 | — | -1.61 ± 0.776 |
| Week 136 | — | -1.65 ± 0.792 |
| Week 144 | — | -1.64 ± 0.836 |
| Week 152 | — | -1.52 ± 0.833 |
| Week 160 | — | -1.28 ± 0.788 |
| Week 168 | — | -1.54 ± 0.657 |
| Week 176 | — | -1.50 ± 0.670 |
| Week 184 | — | -1.89 ± 0.921 |
The Inflammatory Bowel Disease Questionnaire (IBDQ) measures the effects of inflammatory bowel disease on daily function and quality of life. The IBDQ consists of 32 questions which address symptoms as a result of Crohn's disease: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Each question is answered on a scale from 1 (all the time) to 7 (none of the time); the total score ranges from 32 (worst) to 224 (best). Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). Positive values indicate improvement from baseline.
| units on a scale | Risankizumab 180 mg SC |
|---|---|
| Week 0 | 62.48 ± 38.791 |
| Week 24 | 58.72 ± 35.626 |
| Week 48 | 64.03 ± 33.039 |
| Week 72 | 64.14 ± 42.229 |
| Week 96 | 62.38 ± 39.220 |
| Week 120 | 67.28 ± 34.390 |
| Week 144 | 61.34 ± 34.894 |
| Week 168 | 56.36 ± 33.035 |
| Week 192 | 71.17 ± 41.911 |
The Inflammatory Bowel Disease Questionnaire (IBDQ) measures the effects of inflammatory bowel disease on daily function and quality of life. The IBDQ consists of 32 questions which address symptoms as a result of Crohn's disease: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Each question is answered on a scale from 1 (all the time) to 7 (none of the time); the total score ranges from 32 (worst) to 224 (best). Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). Positive values indicate improvement from baseline.
| units on a scale | Risankizumab 180 mg SC |
|---|---|
| Week 0 | 20.44 ± 11.680 |
| Week 24 | 18.26 ± 11.587 |
| Week 48 | 20.29 ± 10.861 |
| Week 72 | 20.64 ± 12.547 |
| Week 96 | 19.12 ± 13.064 |
| Week 120 | 22.25 ± 10.473 |
| Week 144 | 20.46 ± 10.639 |
| Week 168 | 18.44 ± 10.658 |
| Week 192 | 22.67 ± 14.962 |
The Inflammatory Bowel Disease Questionnaire (IBDQ) measures the effects of inflammatory bowel disease on daily function and quality of life. The IBDQ consists of 32 questions which address symptoms as a result of Crohn's disease: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Each question is answered on a scale from 1 (all the time) to 7 (none of the time); the total score ranges from 32 (worst) to 224 (best). Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). Positive values indicate improvement from baseline.
| units on a scale | Risankizumab 180 mg SC |
|---|---|
| Week 0 | 9.9 ± 6.66 |
| Week 24 | 9.1 ± 6.44 |
| Week 48 | 9.6 ± 6.08 |
| Week 72 | 10.1 ± 7.36 |
| Week 96 | 10.3 ± 5.80 |
| Week 120 | 9.8 ± 6.16 |
| Week 144 | 8.9 ± 6.02 |
| Week 168 | 8.2 ± 5.10 |
| Week 192 | 11.8 ± 4.62 |
The Inflammatory Bowel Disease Questionnaire (IBDQ) measures the effects of inflammatory bowel disease on daily function and quality of life. The IBDQ consists of 32 questions which address symptoms as a result of Crohn's disease: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Each question is answered on a scale from 1 (all the time) to 7 (none of the time); the total score ranges from 32 (worst) to 224 (best). Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). Positive values indicate improvement from baseline.
| units on a scale | Risankizumab 180 mg SC |
|---|---|
| Week 0 | 11.04 ± 8.230 |
| Week 24 | 10.57 ± 7.652 |
| Week 48 | 11.64 ± 7.487 |
| Week 72 | 11.20 ± 8.731 |
| Week 96 | 10.59 ± 8.556 |
| Week 120 | 11.92 ± 7.347 |
| Week 144 | 10.93 ± 8.309 |
| Week 168 | 10.87 ± 9.503 |
| Week 192 | 11.67 ± 9.266 |
The Inflammatory Bowel Disease Questionnaire (IBDQ) measures the effects of inflammatory bowel disease on daily function and quality of life. The IBDQ consists of 32 questions which address symptoms as a result of Crohn's disease: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Each question is answered on a scale from 1 (all the time) to 7 (none of the time); the total score ranges from 32 (worst) to 224 (best). Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). Positive values indicate improvement from baseline.
| units on a scale | Risankizumab 180 mg SC |
|---|---|
| Week 0 | 21.09 ± 16.820 |
| Week 24 | 20.79 ± 15.632 |
| Week 48 | 22.55 ± 14.965 |
| Week 72 | 22.23 ± 17.912 |
| Week 96 | 22.41 ± 17.075 |
| Week 120 | 23.35 ± 15.391 |
| Week 144 | 21.03 ± 15.044 |
| Week 168 | 18.87 ± 14.552 |
| Week 192 | 25.00 ± 21.373 |
Concentration of serum high-sensitivity C-reactive Protein (hs-CRP) was analyzed by a central laboratory. It is a general marker of inflammation that is sensitive to acute changes in inflammatory response, and higher levels indicate more inflammation. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). Negative values indicate improvement from baseline.
| mg/L | Risankizumab 180 mg SC |
|---|---|
| Week 0 | -14.64 ± 22.842 |
| Week 8 | -15.84 ± 22.548 |
| Week 24 | -12.76 ± 24.457 |
| Week 40 | -14.32 ± 24.080 |
| Week 56 | -16.11 ± 24.194 |
| Week 72 | -14.40 ± 21.878 |
| Week 88 | -17.07 ± 23.312 |
| Week 104 | -14.44 ± 20.057 |
| Week 120 | -13.81 ± 22.667 |
| Week 128 | -14.87 ± 20.133 |
| Week 136 | -15.78 ± 20.864 |
| Week 152 | -17.03 ± 20.998 |
| Week 160 | -18.43 ± 22.147 |
| Week 176 | -20.49 ± 25.062 |
| Week 184 | -25.01 ± 32.459 |
Fecal calprotectin (FCP) is an indicator of inflammation in the colon with higher levels indicative of higher levels of inflammation. Stool samples were analyzed by a central laboratory for fecal calprotectin levels. Baseline is defined as the last measurement prior to the first dose of the study drug in the feeder study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993). Negative values indicate improvement from baseline.
| μg/g | Risankizumab 180 mg SC |
|---|---|
| Week 0 | -1983.9 ± 3402.12 |
| Week 24 | -2166.4 ± 4035.66 |
| Week 56 | -2277.8 ± 4104.19 |
| Week 88 | -2485.9 ± 4157.37 |
| Week 120 | -2031.9 ± 5187.92 |
| Week 152 | -2631.5 ± 4589.62 |
| Week 184 | -4436.1 ± 7455.55 |
Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from the first dose of study drug until 140 days after the last dose of study drug in the current study or until the first dose of study drug in NCT03105102 (AbbVie M16-000 Sub-study 3), up to 4 years for participants who rolled-over.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Risankizumab 600 mg IV | 0/4 (0%) | 0/4 (0%) | 2/4 (50%) |
| Risankizumab 180 mg SC | 0/65 (0%) | 23/65 (35.4%) | 52/65 (80%) |
| All Risankizumab | 0/65 (0%) | 23/65 (35.4%) | 52/65 (80%) |
| Event | Risankizumab 600 mg IV | Risankizumab 180 mg SC | All Risankizumab |
|---|---|---|---|
| Crohn's diseaseGastrointestinal disorders | 0/4 | 2/65 | 2/65 |
| Intestinal stenosisGastrointestinal disorders | 0/4 | 2/65 | 2/65 |
| Gastroenteritis viralInfections and infestations | 0/4 | 2/65 | 2/65 |
| PeritonitisInfections and infestations | 0/4 | 2/65 | 2/65 |
| Post procedural complicationInjury, poisoning and procedural complications | 0/4 | 2/65 | 2/65 |
| Iron deficiency anaemiaBlood and lymphatic system disorders | 0/4 | 1/65 | 1/65 |
| TachycardiaCardiac disorders | 0/4 | 1/65 | 1/65 |
| Adrenal insufficiencyEndocrine disorders | 0/4 | 1/65 | 1/65 |
| Abdominal pain upperGastrointestinal disorders | 0/4 | 1/65 | 1/65 |
| Dumping syndromeGastrointestinal disorders | 0/4 | 1/65 | 1/65 |
| Event | Risankizumab 600 mg IV | Risankizumab 180 mg SC | All Risankizumab |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 1/4 | 20/65 | 20/65 |
| Ear painEar and labyrinth disorders | 1/4 | 0/65 | 1/65 |
| Abdominal pain upperGastrointestinal disorders | 1/4 | 4/65 | 5/65 |
| HaematocheziaGastrointestinal disorders | 1/4 | 2/65 | 2/65 |
| OdynophagiaGastrointestinal disorders | 1/4 | 0/65 | 1/65 |
| VomitingGastrointestinal disorders | 1/4 | 4/65 | 5/65 |
| Upper respiratory tract infectionInfections and infestations | 1/4 | 7/65 | 7/65 |
| Weight increasedInvestigations | 1/4 | 2/65 | 2/65 |
| Vitamin B12 deficiencyMetabolism and nutrition disorders | 1/4 | 2/65 | 3/65 |
| GastroenteritisInfections and infestations | 0/4 | 15/65 | 15/65 |
Intent-to-Treat population: all participants who received at least one dose of risankizumab in the current study
| Age, Continuous(years) | All Risankizumab |
|---|---|
| Mean | 37.1 ± 12.97 |
| Sex: Female, Male(Participants) | All Risankizumab |
|---|---|
| Female | 36 |
| Male | 29 |
| Race (NIH/OMB)(Participants) | All Risankizumab |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 10 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 55 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Baseline Corticosteroid Use(Participants) | All Risankizumab |
|---|---|
| Yes | 21 |
| No | 44 |
| Missing | 0 |
| Tumor Necrosis Factor (TNF) Antagonist Exposure(Participants) | All Risankizumab |
|---|---|
| Anti-TNF Experienced | 60 |
| Anti-TNF Naive | 5 |
| Missing | 0 |
| Crohn's Disease Activity Index (CDAI)(units on a scale) | All Risankizumab |
|---|---|
| Mean | 304.771 ± 77.9832 |
| High-sensitivity C-Reactive Protein (hs-CRP)(mg/L) | All Risankizumab |
|---|---|
| Mean | 20.315 ± 23.1676 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code
Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
Data sharing details ↗ · www.abbvie.com
Ran from Sep 2015 to primary completion in Jun 2019, 45 months.
Results were first posted in Apr 2020, 10 months after primary completion.
Of 56 industry-sponsored phase 2 interventional studies under Crohn Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 45 months is above that.
Counting every sponsor, half of 83 studies reached it within 34 months; a quarter within 23 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Risankizumab